- Home
- SQFT vs APLM Comparison
SQFT vs APLM Comparison
Compare SQFT & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFT
- APLM
- Stock Information
- Founded
- SQFT 1999
- APLM 2016
- Country
- SQFT United States
- APLM United States
- Employees
- SQFT N/A
- APLM N/A
- Industry
- SQFT Real Estate Investment Trusts
- APLM Blank Checks
- Sector
- SQFT Real Estate
- APLM Finance
- Exchange
- SQFT Nasdaq
- APLM Nasdaq
- Market Cap
- SQFT 6.2M
- APLM 6.9M
- IPO Year
- SQFT 2020
- APLM N/A
- Fundamental
- Price
- SQFT $5.15
- APLM $5.33
- Analyst Decision
- SQFT
- APLM
- Analyst Count
- SQFT 0
- APLM 0
- Target Price
- SQFT N/A
- APLM N/A
- AVG Volume (30 Days)
- SQFT 12.4K
- APLM 26.7K
- Earning Date
- SQFT 08-13-2025
- APLM 08-13-2025
- Dividend Yield
- SQFT N/A
- APLM N/A
- EPS Growth
- SQFT N/A
- APLM N/A
- EPS
- SQFT N/A
- APLM N/A
- Revenue
- SQFT $18,260,398.00
- APLM $198,000.00
- Revenue This Year
- SQFT $23.63
- APLM $415.15
- Revenue Next Year
- SQFT N/A
- APLM N/A
- P/E Ratio
- SQFT N/A
- APLM N/A
- Revenue Growth
- SQFT N/A
- APLM N/A
- 52 Week Low
- SQFT $4.19
- APLM $4.47
- 52 Week High
- SQFT $8.77
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- SQFT 51.05
- APLM 44.49
- Support Level
- SQFT $4.55
- APLM $5.33
- Resistance Level
- SQFT $5.77
- APLM $6.56
- Average True Range (ATR)
- SQFT 0.37
- APLM 0.54
- MACD
- SQFT 0.09
- APLM -0.05
- Stochastic Oscillator
- SQFT 56.96
- APLM 33.11
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.